Bank of Montreal Can Takes Position in Boston Scientific Corp. (BSX)
Bank of Montreal Can purchased a new stake in shares of Boston Scientific Corp. (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 569,528 shares of the company’s stock, valued at approximately $13,309,000.
A number of other institutional investors have also recently modified their holdings of BSX. IFP Advisors Inc increased its position in shares of Boston Scientific Corp. by 55.5% in the first quarter. IFP Advisors Inc now owns 6,242 shares of the company’s stock valued at $117,000 after buying an additional 2,228 shares in the last quarter. NN Investment Partners Holdings N.V. purchased a new position in shares of Boston Scientific Corp. during the first quarter valued at $145,000. FDO Partners LLC purchased a new position in shares of Boston Scientific Corp. during the first quarter valued at $209,000. Rockefeller Financial Services Inc. bought a new position in Boston Scientific Corp. during the second quarter valued at approximately $256,000. Finally, Checchi Capital Advisers LLC increased its position in Boston Scientific Corp. by 3.4% in the second quarter. Checchi Capital Advisers LLC now owns 10,944 shares of the company’s stock valued at $256,000 after buying an additional 358 shares during the period. 92.06% of the stock is currently owned by institutional investors and hedge funds.
Boston Scientific Corp. (NYSE:BSX) traded up 2.15% during mid-day trading on Friday, reaching $23.80. 8,829,535 shares of the company were exchanged. Boston Scientific Corp. has a 1-year low of $15.67 and a 1-year high of $24.79. The stock’s 50-day moving average price is $23.84 and its 200-day moving average price is $22.36. The stock’s market capitalization is $32.39 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its earnings results on Thursday, July 28th. The company reported $0.27 earnings per share for the quarter, hitting the consensus estimate of $0.27. The firm earned $2.13 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Boston Scientific Corp. had a positive return on equity of 22.66% and a negative net margin of 4.34%. The firm’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.22 earnings per share. On average, equities research analysts anticipate that Boston Scientific Corp. will post ($0.02) EPS for the current fiscal year.
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. reissued a “buy” rating on shares of Boston Scientific Corp. in a report on Sunday, July 17th. TheStreet downgraded shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Zacks Investment Research raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Wednesday, July 13th. Citigroup Inc. boosted their target price on shares of Boston Scientific Corp. from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Finally, Leerink Swann reissued a “buy” rating on shares of Boston Scientific Corp. in a report on Friday, July 29th. Six research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Boston Scientific Corp. presently has an average rating of “Buy” and an average price target of $25.03.
In other Boston Scientific Corp. news, CEO Michael F. Mahoney sold 44,400 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $24.44, for a total value of $1,085,136.00. Following the completion of the sale, the chief executive officer now owns 1,388,177 shares in the company, valued at $33,927,045.88. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP John Bradley Sorenson sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $23.90, for a total value of $59,750.00. Following the completion of the sale, the senior vice president now owns 12,615 shares of the company’s stock, valued at approximately $301,498.50. The disclosure for this sale can be found here. Corporate insiders own 1.31% of the company’s stock.
Boston Scientific Corp. Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.
Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.